2017 American Transplant Congress
Multiple Dosing of Anti-C1s Antibody TNT009 – Effect on HLA Antibody-Triggered Complement Activation in Healthy Volunteers and Kidney Transplant Recipients with Antibody-Mediated Rejection.
Study purpose. Complement inhibition may be an attractive strategy to prevent antibody-mediated allograft injury. One promising therapeutic target may be the enzymatic activity of key…2017 American Transplant Congress
Early Antibody-Mediated Rejection C4d Status Remains a Marker of Prognosis in HLA-Incompatible Kidney Transplantation.
1CHP, Porto, Portugal; 2IPST, Porto, Portugal
Banff criteria for the diagnosis of antibody-mediated rejection (AMR) in kidney transplantation (KT) was recently updated to include the entity of C4d negative AMR, if…2017 American Transplant Congress
De Novo Donor-Specific Antibody Formation After Kidney Retransplant Is Associated with Specificity Against Class I.
Retransplant (RTx) patients are often sensitized due to donor-specific antibody (DSA) formation, with higher acute rejection rates during subsequent transplants vs patients without DSA. However,…2017 American Transplant Congress
Pre Transplant Donor Specific Antibodies and Clinical Outcomes in Kidney Transplant Recipient on Steroid Free Maintenance Immunosupression Regimen.
Background: The clinical relevance of pre transplant donor specific antibodies has been reported in few clinical studies with respect to its effect on the risk…2017 American Transplant Congress
Higher Tacrolimus Blood Levels Predict Better Graft Survival in Kidney Recipients with De Novo DSA.
Background: De novo anti-HLA donor specific antibodies (dnDSA) are associated with poorer outcomes in kidney transplant recipients. Nonetheless, their monitoring post transplant is not widespread,…2017 American Transplant Congress
Microcirculation Inflammation in Kidney Allograft Biopsies.
Introduction: The Microcirculation Inflammation (IM) in kidney transplants is a strong predictor of graft loss inde-pedent of C4d and donor specific antibody(DSA)ObjetiveAnalysis of kidney allograft…2017 American Transplant Congress
A Phase Ib, Open Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients with End-Stage Renal Disease.
1U.Cincinnati, OH; 2Prolong Pharmaceuticals, NJ
Purpose:The endeavor and resources spent to study desensitization haven't been matched by an effort to investigate strategies to prevent sensitization.The purpose of this study was…2017 American Transplant Congress
Optimization of Extended-Release Tacrolimus Dose with Mycophenolate Mofetile Based Immunosuppression in De Novo Kidney Transplant Recipients: 2 Years Outcome.
Purpose: Once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well determined. We have validated the institutional…2016 American Transplant Congress
Ibrutinib Suppresses Alloantibody Responses in A Mouse Model of Allosensitization: A Preliminary Report.
CTC/Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
Background Ibrutinib is a Bruton tyrosine Kinase (BTK) antagonist that inhibits B cell receptor (BCR) signaling, therefore blocking B cell activation. Ibrutinib is approved by…2016 American Transplant Congress
Frequency and Utility of Donor-Specific Antibody Testing in Simultaneous Liver Kidney Transplant.
Introduction: The risk of antibody mediated rejection (AMR) in simultaneous liver kidney (SLK) recipients is thought to be lower than in kidney alone patients due…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 40
- Next Page »